Actym Therapeutics utilizes its STACT™ platform, an engineered S. Typhimurium bacterial delivery system, to locally produce and amplify therapeutic payloads for the treatment of cancer and fibrotic diseases. This approach minimizes systemic toxicity associated with traditional therapeutic administration methods while enhancing treatment efficacy at the disease site.

Alamar Biosciences develops NULISA™ technology, which enables the detection of protein biomarkers from a single liquid biopsy sample with attomolar sensitivity and a dynamic range of up to 12 logs. This technology addresses the challenge of early disease diagnosis by providing researchers with a high-throughput platform for profiling clinically relevant biomarkers across various diseases, including cancer and neurodegenerative disorders.

Develops proprietary genomic editors that target the root causes of genetic diseases by selecting optimal editing tools based on disease-specific pathology. This approach enables the discovery and development of potentially curative genomic medicines, with a focus on liver and central nervous system disorders.

Arima Genomics utilizes 3D genomics and Hi-C technology to provide detailed insights into the sequence, structure, and regulatory landscape of genomes, enabling the identification of novel biomarkers and therapeutic targets. Their solutions facilitate rapid genome assembly and analysis, addressing the need for comprehensive genomic characterization in cancer research and human health.

Attovia is developing a pipeline of biotherapeutics for immune-mediated diseases and oncology using its proprietary ATTOBODY platform, which enables the creation of bispecific and multispecific antibodies with picomolar affinity and enhanced tissue penetration. This technology addresses the lack of effective treatment options for patients by providing first-in-class mechanisms of action that improve therapeutic efficacy.

This company develops genomic technology focused on improving the safety and characterization of gene editing tools for cell and gene therapies. Their INDUCE-seq platform enables developers to accurately detect on- and off-target edits associated with gene editing systems like CRISPR. This technology supports the standardization and acceleration of safer gene-edited therapeutic development.

Bullseye Biosciences provides a directed‑evolution platform that automates library construction and uses next‑generation sequencing combined with AI analytics to screen billions of protein variants in a single campaign. The service delivers fully characterized, IP‑ready therapeutic candidates and associated data to pharma, biotech, and academic partners for preclinical development or licensing.

The startup has developed a protein engineering platform that employs artificial intelligence and machine learning to analyze protein structures and predict interactions based on their physical properties. This technology enables researchers to efficiently design synthetic proteins for drug development, addressing the challenges of time-consuming and resource-intensive proteomics processes.

Delfi Diagnostics utilizes the DELFI method, which employs advanced machine learning and next-generation sequencing to analyze cell-free DNA fragments from non-invasive blood samples for early cancer detection. This approach enhances the identification of previously unrecognized cancer-associated DNA fragments, addressing the limitations of existing liquid biopsy methods that rely solely on known mutations.

Fluent Biosciences offers PIPseq™, a technology that enables single-cell RNA sequencing without complex microfluidic instrumentation, allowing for the rapid and sensitive analysis of individual cells. This approach addresses the challenges of high ambient RNA background and sequencing bias, providing researchers with a cost-effective and scalable solution for diverse applications in cancer, immunology, and neuroscience.

Fuze Health provides a unified, API‑driven platform that integrates disease screening, genomics, telehealth, digital pharmacy, and patient engagement into a single digital ecosystem. The solution enables health systems, plans, employers, and life‑science companies to streamline data, improve early detection, and deliver personalized, adherent care through AI‑powered analytics and real‑time support.

Hepta develops a liquid biopsy platform that uses AI to interpret epigenetic patterns from cell-free DNA in blood to reveal liver biology. This non-invasive technology enables earlier detection and monitoring of metabolic dysfunction-associated steatohepatitis (MASH) in routine clinical care. The platform aims to provide tissue-level insight from a simple blood draw to guide timely treatment decisions for chronic liver diseases.

Iambic Therapeutics utilizes a physics-based AI-driven drug discovery platform to explore chemical space and identify novel mechanisms of action for drug candidates. The platform accelerates the development of first-in-class therapeutics by optimizing target product profiles and delivering high-quality leads at a pace significantly faster than traditional methods.

Infinity Bio provides high-throughput antibody reactome profiling services using its proprietary MIPSA technology. This service decodes antibody binding interactions against comprehensive antigen libraries for various hosts and isotypes. The company supports research across infectious diseases, autoimmunity, vaccine development, and precision medicine by delivering detailed immune response data.

This company develops small molecule therapeutics aimed at treating age-related diseases by engineering aging medicine. They utilize an integrated platform combining optogenetics, chemistry, and AI to unravel complex biology with high precision. This approach allows for the systematic exploration of chemical space to unlock novel therapeutic opportunities.

Kallyope develops oral small-molecule therapeutics targeting metabolic, neurological, and gastrointestinal diseases by utilizing its Klarity™ platform to explore gut-brain signaling pathways. The company focuses on conditions such as obesity, diabetes, migraines, and celiac disease, aiming to provide effective and well-tolerated treatment options.

Kodikaz is a gene therapy platform that employs targeted delivery systems to selectively destroy cancer cells while preserving healthy tissue. This technology provides a more effective treatment option for patients by reducing the adverse effects commonly associated with traditional cancer therapies.

Lightcast provides Envisia, a high‑throughput platform that isolates thousands of single cells and directly measures functional behaviours such as biomolecule secretion, cell‑cell communication, and susceptibility to targeted killing. The system combines microfluidic isolation, sensitive detection, and an integrated analytics suite to generate quantitative functional profiles that support antibody discovery, cellular therapy development, and other translational research applications.

NanoCellect provides microfluidic cell sorters that operate below 2 psi to minimize shear stress and preserve cell viability. The platform uses disposable sterile cartridges, accepts native culture media without sheath fluid, and includes a touchscreen interface with single‑cell deposition into 96‑ or 384‑well plates for downstream assays.

NuCicer uses a two‑decade‑old global genetic library of wild and cultivated chickpeas to breed high‑protein, non‑GMO varieties through nature‑based precision breeding. Their chickpea ingredients—whole beans, functional flours, protein powders, and custom trait packages—offer up to 75% more protein, improved nutrition, and better functional properties while requiring less water and supporting regenerative agriculture, enabling food and beverage brands to create affordable, gluten‑free, plant‑based products.

Pattern Bioscience utilizes single-cell microbiology to provide rapid identification and antimicrobial susceptibility testing results within hours, bypassing traditional culture methods. The company addresses the issue of antibiotic misuse in hospitals, which leads to ineffective treatments and contributes to antibiotic resistance.

Pluton Biosciences utilizes its Micromining Innovation Engine to rapidly discover and clone novel microbes for applications in biopesticides, crop protection, and bioremediation. This platform addresses the need for sustainable solutions in agriculture and environmental management by enabling the production of all-natural bioproducts that enhance human health and combat climate change.

Precede Biosciences provides a liquid‑biopsy platform that extracts circulating chromatin and DNA methylation from 1 mL of plasma to deliver genome‑wide, quantitative profiles of transcriptional activity, pathway activation, and cell‑state changes. Their proprietary machine‑learning pipelines translate these epigenomic signals into interpretable reports for longitudinal disease monitoring, supporting drug development, patient selection, and response tracking for pharmaceutical and biotech companies.

Predicta develops a blood-based oncology platform that utilizes multi-omics and liquid biopsy technologies to provide non-invasive diagnostics, replacing the need for bone marrow biopsies. This approach enables early disease detection and personalized treatment guidance, improving patient outcomes through actionable insights derived from comprehensive patient data analysis.